Target Price | $61.75 |
Price | $40.72 |
Potential | 51.65% |
Number of Estimates | 20 |
20 Analysts have issued a price target Moderna 2026 . The average Moderna target price is $61.75. This is 51.65% higher than the current stock price. The highest price target is $212.00 420.63% , the lowest is $27.00 33.69% . | |
A rating was issued by 28 analysts: 7 Analysts recommend Moderna to buy, 17 to hold and 4 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Moderna stock has an average upside potential 2026 of 51.65% . Most analysts recommend the Moderna stock at Hold. |
22 Analysts have issued a sales forecast Moderna 2024 . The average Moderna sales estimate is $3.2b . This is 36.41% lower than the revenue of the last 12 months(TTM). The highest sales forecast is $3.5b 31.11% , the lowest is $3.0b 40.53% .
This results in the following potential growth metrics:
2023 | $6.8b | 64.21% |
---|---|---|
2024 | $3.2b | 52.84% |
2025 | $2.6b | 20.52% |
2026 | $3.1b | 20.38% |
2027 | $4.1b | 34.13% |
2028 | $5.3b | 28.08% |
10 Analysts have issued an Moderna EBITDA forecast 2024. The average Moderna EBITDA estimate is $-3.6b . This is 51.28% lower than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $-3.1b 28.82% , the lowest is $-4.0b 68.32% .
This results in the following potential growth metrics and future EBITDA Margins:
2023 | $-3.6b | 137.72% |
---|---|---|
2024 | $-3.6b | 1.12% |
2025 | $-3.4b | 5.20% |
2026 | $-2.7b | 21.82% |
2027 | $-1.5b | 44.65% |
2023 | -53.01% | 205.37% |
---|---|---|
2024 | -111.15% | 109.67% |
2025 | -132.58% | 19.28% |
2026 | -86.10% | 35.06% |
2027 | -35.53% | 58.73% |
15 Moderna Analysts have issued a net profit forecast 2024. The average Moderna net profit estimate is $-3.6b . This is 59.99% lower than the net profit for the last 12 months(TTM). The highest net profit forecast is $-2.8b 25.43% , the lowest is $-4.0b 79.56% .
This results in the following potential growth metrics and future Net Margins:
2023 | $-4.8b | 161.39% |
---|---|---|
2024 | $-3.6b | 24.54% |
2025 | $-3.5b | 1.96% |
2026 | $-2.8b | 20.47% |
2027 | $-2.1b | 23.44% |
2028 | $-1.9b | 12.70% |
2023 | -69.46% | 271.51% |
---|---|---|
2024 | -111.13% | 60.00% |
2025 | -137.09% | 23.36% |
2026 | -90.57% | 33.93% |
2027 | -51.70% | 42.92% |
2028 | -35.23% | 31.86% |
15 Analysts have issued a Moderna forecast for earnings per share. The average Moderna <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is $-9.31 . This is 59.97% lower than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is $-7.30 25.43% , the lowest is $-10.45 79.55% .
This results in the following potential growth metrics and future valuations:
2023 | $-12.34 | 161.39% |
---|---|---|
2024 | $-9.31 | 24.55% |
2025 | $-9.13 | 1.93% |
2026 | $-7.26 | 20.48% |
2027 | $-5.56 | 23.42% |
2028 | $-4.85 | 12.77% |
Current | -6.99 | 35.87% |
---|---|---|
2024 | -4.37 | 37.48% |
2025 | -4.46 | 2.06% |
2026 | -5.61 | 25.78% |
2027 | -7.33 | 30.66% |
2028 | -8.39 | 14.46% |
Based on analysts' sales estimates for 2024, the Moderna stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of 3.15 and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of 4.86 .
This results in the following potential growth metrics and future valuations:
Current | 2.00 | 44.60% |
---|---|---|
2024 | 3.15 | 57.45% |
2025 | 3.96 | 25.82% |
2026 | 3.29 | 16.93% |
2027 | 2.45 | 25.45% |
2028 | 1.92 | 21.93% |
Current | 3.09 | 27.84% |
---|---|---|
2024 | 4.86 | 57.26% |
2025 | 6.11 | 25.82% |
2026 | 5.08 | 16.93% |
2027 | 3.79 | 25.45% |
2028 | 2.96 | 21.93% |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.